Lytix Biopharma AS (LYTIX) — Strategic Asset Allocation Index
Lytix Biopharma AS (LYTIX) has a Strategic Asset Allocation Index of 3.4% as of December 2025. Strategic assets (PP&E of Nkr2.09 Million plus long-term investments of Nkr-) total Nkr2.09 Million, measured against net assets of Nkr61.75 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Lytix Biopharma AS balance sheet quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Lytix Biopharma AS Strategic Asset Allocation Index (2017–2025)
This chart shows how Lytix Biopharma AS's Strategic Asset Allocation Index has evolved across 6 annual periods from 2017 to 2025. As of December 2025, the index stands at 3.4%, representing strategic assets of Nkr2.09 Million against net assets of Nkr61.75 Million NOK. For live market cap and overall valuation, see LYTIX stock market capitalisation.
Annual Strategic Asset Allocation Index for Lytix Biopharma AS (2017–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Lytix Biopharma AS from 2017 to 2025, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See LYTIX book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (NOK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 3.4% | Nkr2.09 Million | Nkr2.09 Million | Nkr- | Nkr61.75 Million | ▲ +0.9 pp |
| 2024 | 2.4% | Nkr2.63 Million | Nkr2.63 Million | Nkr- | Nkr107.89 Million | ▲ +1.4 pp |
| 2023 | 1.1% | Nkr548.00K | Nkr548.00K | Nkr- | Nkr51.32 Million | ▲ +1.0 pp |
| 2022 | 0.1% | Nkr124.00K | Nkr124.00K | Nkr- | Nkr135.13 Million | ▲ +0.1 pp |
| 2018 | 0.0% | Nkr0.00 | Nkr0.00 | Nkr- | Nkr41.05 Million | ▼ -0.1 pp |
| 2017 | 0.1% | Nkr6.00K | Nkr6.00K | Nkr- | Nkr11.79 Million | — |